Acer Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACER Nasdaq 8731 https://acertx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acer Therapeutics Inc

Acer Therapeutics Inc. (ACER) Reports Q1 Loss, Misses Revenue Estimates - May 16th, 2022 10:55 pm
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update - May 16th, 2022 8:01 pm
OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates - May 12th, 2022 12:15 pm
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients - May 9th, 2022 12:30 pm
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference - May 6th, 2022 12:30 pm
Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference - May 5th, 2022 12:30 pm
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting - Apr 12th, 2022 12:30 pm
PC sales down 5% in Q1 2022 after two years of growth - Apr 11th, 2022 7:48 pm
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome - Apr 4th, 2022 12:30 pm
Midday Stock Movers: Twitter, Tesla, Hertz Rally, DWAC Continues Decline - Apr 4th, 2022 11:50 am
Acer Therapeutics Regains Compliance with Nasdaq Listing Standard - Mar 31st, 2022 12:30 pm
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause - Mar 30th, 2022 12:30 pm
SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021 - Mar 28th, 2022 11:00 am
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities - Mar 7th, 2022 11:15 am
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update - Mar 2nd, 2022 10:18 pm
Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer - Feb 22nd, 2022 1:30 pm
Is Acer Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? (Revised) - Feb 8th, 2022 7:44 pm
Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference - Feb 1st, 2022 1:30 pm
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences - Jan 27th, 2022 1:30 pm
Is Opexa Therapeutics, Inc. (ACER) Outperforming Other Medical Stocks This Year? - Jan 13th, 2022 2:40 pm